WO2020246807A3 - Pharmaceutical composition for treating cancer, containing naphthoquinone compound - Google Patents

Pharmaceutical composition for treating cancer, containing naphthoquinone compound Download PDF

Info

Publication number
WO2020246807A3
WO2020246807A3 PCT/KR2020/007223 KR2020007223W WO2020246807A3 WO 2020246807 A3 WO2020246807 A3 WO 2020246807A3 KR 2020007223 W KR2020007223 W KR 2020007223W WO 2020246807 A3 WO2020246807 A3 WO 2020246807A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
treating cancer
cancer
naphthoquinone compound
nad
Prior art date
Application number
PCT/KR2020/007223
Other languages
French (fr)
Korean (ko)
Other versions
WO2020246807A2 (en
Inventor
이휘성
이은주
고인석
윤민혁
Original Assignee
주식회사 엘마이토테라퓨틱스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 엘마이토테라퓨틱스 filed Critical 주식회사 엘마이토테라퓨틱스
Publication of WO2020246807A2 publication Critical patent/WO2020246807A2/en
Publication of WO2020246807A3 publication Critical patent/WO2020246807A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention relates to a pharmaceutical composition for treating cancer, containing a naphthoquinone compound or a pharmaceutically acceptable salt, hydrate, solvate, enantiomer, diastereomer, tautomer or prodrug thereof, the composition increasing the ratio of NAD+ and NAD+/NADH through activity with respect to NQO1 in vivo, suppressing the production of lactate produced through glycolysis, which is excessively increased during the metabolic process of cancer cells, so as to reduce the amount of lactate to be released into a tumor microenvironment, thereby enhancing the activity of immune cells and, as a result, allow the activated immune cells to eliminate cancer cells, and thus the present invention can be used in the treatment of cancer.
PCT/KR2020/007223 2019-06-04 2020-06-03 Pharmaceutical composition for treating cancer, containing naphthoquinone compound WO2020246807A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20190066241 2019-06-04
KR10-2019-0066241 2019-06-04

Publications (2)

Publication Number Publication Date
WO2020246807A2 WO2020246807A2 (en) 2020-12-10
WO2020246807A3 true WO2020246807A3 (en) 2021-01-21

Family

ID=73653026

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2020/007223 WO2020246807A2 (en) 2019-06-04 2020-06-03 Pharmaceutical composition for treating cancer, containing naphthoquinone compound

Country Status (1)

Country Link
WO (1) WO2020246807A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080047972A (en) * 2006-11-27 2008-05-30 주식회사 엠디바이오알파 Anticancer composition containing naphthoquinone-based compound for intestine delivery system
WO2018005279A1 (en) * 2016-06-27 2018-01-04 Systems Oncology, Llc Combination chemotherapies
CN109481438A (en) * 2018-11-24 2019-03-19 新乡医学院 Application of 2- amino naphtho- [1,2-d] thiazole -4,5- diketone in tumor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080047972A (en) * 2006-11-27 2008-05-30 주식회사 엠디바이오알파 Anticancer composition containing naphthoquinone-based compound for intestine delivery system
WO2018005279A1 (en) * 2016-06-27 2018-01-04 Systems Oncology, Llc Combination chemotherapies
CN109481438A (en) * 2018-11-24 2019-03-19 新乡医学院 Application of 2- amino naphtho- [1,2-d] thiazole -4,5- diketone in tumor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HUANG HUIDAN; YAN MING; CHEN JIANQIU; YUAN BIAO; CHEN GUITANG; CHENG SHUJIE; HUANG DECHUN; GAO ZHEN; CAO CHONGJIANG: "Identification ofortho-naphthoquinones as anti-AML agents by highly efficient oxidation of phenols", BIOORGANIC CHEMISTRY, vol. 86, 18 January 2019 (2019-01-18), pages 97 - 102, XP085657577, ISSN: 0045-2068, DOI: 10.1016/j.bioorg.2019.01.025 *
XIANG LI , JINLEI BIAN , NAN WANG , XUE QIAN , JING GU , TONG MU , JUN FAN , XIUWEN YANG , SHANGZHEN LI , TINGLING YANG , HAOPENG : "Novel naphtho[2,1-d]oxazole-4,5-diones as NQO1 substrates with improved aqueous solubility: Design, synthesis, and in vivo antitumor evaluation", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 24, no. 5, 16 January 2016 (2016-01-16), pages 1006 - 1013, XP029418885, ISSN: 0968-0896, DOI: 10.1016/j.bmc.2016.01.024 *

Also Published As

Publication number Publication date
WO2020246807A2 (en) 2020-12-10

Similar Documents

Publication Publication Date Title
WO2020102804A3 (en) Pharmaceutical combination for treatment of cancer
NZ602675A (en) Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
RU2004126950A (en) USE OF CO-EMITTING COMPOUNDS IN THE PRODUCTION OF A MEDICINE FOR TREATMENT OF INFLAMMATORY DISEASES
CA2560058A1 (en) A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis
CA2501651A1 (en) Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
CA2464758A1 (en) Combination therapy comprising zd6474 and a taxane
IL300151A (en) Combinations for the treatment of cancer
MX2020001342A (en) Use of gaboxadol in the treatment of diabetes and related conditions.
US20220324788A1 (en) Compositions Comprising Oxo-Derivatives of Fatty Acids and Methods of Making and Using Same
MX2023001671A (en) Method and compound for use, in treating and/or preventing netosis.
MX2023006883A (en) Methods of treating prostate cancer.
MX2022014192A (en) Methods of treating prostate cancer.
RU2011135417A (en) ORGANIC COMPOUNDS
WO2020246807A3 (en) Pharmaceutical composition for treating cancer, containing naphthoquinone compound
US20150335624A1 (en) Compositions and methods for using huperzine and analogs thereof
EP3011972A1 (en) Medicinal composition for promoting synthesis of protoporphyrin ix
WO2017181193A3 (en) Methods and compounds for stimulating read-through of premature termination codons
WO2023122782A3 (en) Indoles, indazoles, and related analogs for inhibiting yap/taz-tead
WO2019241641A3 (en) Cancer treatment methods
MX2020013076A (en) Ascorbic acid and quinone compounds in combination with an antiparasitic agent for treating a parasitic disease.
US20100062077A1 (en) Pyrrolo[1,2-a]imidazoledione effective in the treatment of peripheral neurotoxicity induced by chemotherapeutic agents
NZ587941A (en) Methods to inhibit tumor cell growth by using lansoprazole
CA2531620A1 (en) Cancer combination therapy comprising azd2171 and zd1839
RU2018114922A (en) TREATMENT OF Focal Alopecia
WO2021102356A8 (en) Combination therapy of a coenzyme q10 compound and radiation therapy for treatment of glioma

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20817866

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20817866

Country of ref document: EP

Kind code of ref document: A2